Classifications: antiviral; Therapeutic: antiinfluenza
Pregnancy Category: C
5 mg/Rotadisk blister
Inhibitor of influenza A and B viral enzyme; does not permit the release of newly formed viruses from the surface of the
Prevents viral spread across the mucus lining of the respiratory tract, and inhibits the replication of influenza A and
B virus. Relieves flu-like symptoms.
Uncomplicated acute influenza in patients symptomatic <2 d.
Hypersensitivity to zanamivir or milk protein; severe renal impairment, renal failure; pregnancy (category C); COPD; severe
Concurrent use of inhaled medication with inhaled zanamivir; renal impairment; cardiac disease; older adults; severe metablic
disease; lactation. Safety and efficacy in children <7 y are unknown. Safe use in prophylactic treatment for children <5
Route & Dosage
Adult/Child (>7 y): Inhaled 2 inhalations (one 5 mg blister/inhalation) b.i.d. (approximately 12 h apart) x 5 d
Adult/Child (>5 y): Inhaled 2 inhalations daily for 10 d (household prophylaxis) or 2 inhalations daily for 28 d (community outbreak)
- Initiate within 48 h of onset of flu-like symptoms.
- Give any scheduled inhaled bronchodilator before zanamivir.
Adverse Effects (≥1%)Body as a Whole:
Nausea, diarrhea, vomiting. Respiratory:
Nasal symptoms, bronchitis
, cough, sinusitis; ear, nose, throat infection.
No clinically significant interactions established.
417% of inhaled dose is systemically absorbed. Peak:
12 h. Distribution:
<10% protein bound. Metabolism:
Not metabolized. Elimination:
In urine. Half-Life:
Patient & Family Education
- Start within 48 h of onset of flu-like symptoms for most effective response.
- Use any scheduled inhaled bronchodilator first; then use zanamivir.